CIOMS pharmacovigilance: what the CIOMS I form is used for
CIOMS I is a form for reporting suspected adverse drug reactions. It differs from E2B case exchange, and it does not set India's reporting deadline.
In CIOMS pharmacovigilance, the CIOMS I form is a standardized format developed for manufacturers to report suspected adverse drug reactions. CIOMS stands for the Council for International Organizations of Medical Sciences. It is an international, non-governmental, non-profit organization, and its work includes guidance on medical product safety. The organization, the guidance and the form are separate. None of them sets an Indian reporting deadline.
What CIOMS I is used for
The CIOMS I working group developed a method for manufacturers to report suspected adverse drug reactions. Its work covered standardized definitions, procedures, and a reporting format. The original scope was post-marketing reactions occurring in one country and reported to authorities in other countries where the drug was marketed. CIOMS explains that history on its form page. That is how the form was built. It is not a current rule that every authority must accept it.
A suspected-reaction report is not proof that the medicine caused the reaction.
The form helps you record a suspected reaction. It does not, on its own, meet a reporting obligation. Before you use it for a submission, check whether the recipient accepts that format and which instructions apply to your role. Don't infer acceptance from the form's availability.
CIOMS I, E2B and periodic reports are different
A reporting form and an electronic exchange standard answer different questions. CIOMS states that the CIOMS I form is a reporting form, not primarily intended for electronic exchange between databases, and it describes ICH E2B as standardizing the data elements for electronic transmission of individual case safety reports, or ICSRs.
| Term | What it concerns |
|---|---|
| CIOMS I | A standardized suspected-adverse-reaction reporting form |
| E2B | Data elements for electronic transmission of ICSRs |
| Periodic safety summaries | Periodic reporting, not the CIOMS I case form |
The periodic side comes from a separate 1992 CIOMS Working Group II report, International Reporting of Periodic Drug-Safety Update Summaries. The same CIOMS page discusses both reports. A PSUR concerns that periodic safety reporting, not the CIOMS I individual-case format. That CIOMS page does not set an Indian PSUR schedule.
But a completed PDF is not an electronic ICSR submission. The form also does not start an expedited-reporting clock.
What to check before reporting in India
Start with your role. The Indian Pharmacopoeia Commission's PvPI FAQ, last updated on 2 January 2019, says healthcare professionals and patients or consumers can report adverse reactions. It encourages reports of suspected reactions, known or unknown, serious or non-serious. Healthcare professionals can fill in the Suspected Adverse Drug Reaction Reporting Form. Consumers can fill in the Medicines Side Effect Reporting Form (for consumers).
The FAQ describes healthcare-professional and consumer reporting, not marketing authorization holder deadlines. For marketing authorization holder work, open the IPC guidance-document index, which lists a pharmacovigilance guidance document for marketing authorization holders (version 2.0), and then check the authority's current reporting instructions for your role before you send anything. Confirm the accepted format, the submission route and the deadline as separate checks. Choosing a form does not establish when or where a report must be sent. The FAQ does not establish that India requires the CIOMS I form.
RegAffairs AI has an answer to what CIOMS is used for in pharmacovigilance.